Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition

Journal of the American College of Cardiology

Volumn 35, Issue 3, 2000, Pages 796-801

  Schirger, John A ^a   Grantham, J Aaron ^a   Kullo, Iftikhar J ^a   Jougasaki, Michihisa ^a   Wennberg, Paul W ^a   Chen, Horng H ^a   Lisy, Ondrej ^a   Miller, Virginia ^a   Simari, Robert D ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BRAIN NATRIURETIC PEPTIDE; BROXURIDINE; CANDOXATRIL; CYCLIC GMP; ENKEPHALINASE INHIBITOR; HORMONE RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROMA; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FETAL CALF SERUM; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOLATED ARTERY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; ARTERIOSCLEROSIS; CELL DIVISION; CELLS, CULTURED; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PHENYLEPHRINE; RABBITS; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 0034162892     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00593-8     Document Type: Article

References (30)

1. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide . J Clin Invest. 87:1991;1402-1412.
2. Stingo A.J., Clavell A.L., Heublein D.M., Wei C.M., Pittelkow M.R., Burnett J.C. Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol. 263:1992;H1318-H1321.
3. DeBold A.J., Borenstin H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1981;89-94.
4. Burnett J.C. Jr, Granger J.P., Opgenorth T.F. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Phsiol. 247:1984;F863-F866.
5. Koller K.J., Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation. 86:1992;1081-1088.
6. Chang M., Lowe D.G., Lewis M., Hellmiss R., Chan E., Goeddel D.V. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature. 341:1989;69-72.
7. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 274:1998;H1684-H1689.
8. Suga S.K., Nakao K., Mukoyama Y., et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide. Endocrinology. 130:1992;229-239.
9. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
10. Supaporn T., Wennberg P.W., Wei C.M., Kinoshita M., Matsuda Y., Burnett J.C. Jr. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci. 90:1996;357-362.
11. Lopez M.J., Wong S.K., Kishinoto I., et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 378:1995;65-68.
12. Margulies K.B., Barclay P.L., Burnett J.C. Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 91:1995;2036-2042.
13. Kugiyama K., Sugiyama S., Matsumura T., Ohta Y., Doi H., Yasue H. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Arterioscler Thromb Vasc Biol. 16:1996;1080-1087.
14. Kahler C.M., Schratzberger P., Wiedermann C.J. Response of vascular smooth muscle cells to the neuropeptide secretoneurin. Arterioscler Thromb Vasc Biol. 17:1997;2029-2035.
15. Steiner A.L., Parker C.W., Kipnis D.M. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem. 247:1972;1106-1113.
16. Grantham J.A., Schirger J.A., Williamson E.E., et al. Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol. 31:(Suppl 1):1998;S22-S26.
17. Abell T.J., Richards A.M., Ikram H., Espiner E.A., Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun. 160:1989;1392-1396.
18. Kariya K., Kawahara Y., Araki S., Fukuzaki H., Takai Y. Antiproliferative action of GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis. 80:1989;143-147.
19. Furuya M., Takehisa M., Minamitake Y., Kitajima Y., Hayashi Y. Novel natriuretic peptide, CNP, potently stimulates cyclic GMP production in rat cultured VSMCs. Biochem Biophys Res Commun. 170:1990;201-208.
20. Furuya M., Yoshida M., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat VSMCs. Biochem Biophys Res Commun. 177:1991;927-931.
21. Porter JG, Protter AA. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Phsiol 1992;263:C1001-6.
22. Mattingly M.T., Clavell A.L., Brandt R.R., Wei C.M., Barclay P., Burnett J.C. Jr. Potentiation of the renal actions of canine brain natriuretic peptide by neutral endopeptidase inhibition (abstr). Am J Hypertens. 7:1994;14A.
23. Mukoyama M., Nakao K., Hosoda K., et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy evidence of brain natriuretic peptide as an emergency cardiac hormone against ventricular overload . J Clin Invest. 96:1995;1280-1287.
24. Kohno M., Yokokawa K., Yasunari K., et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res. 81:1997;585-590.
25. Wei C.M., Miller V.M., Schaff H.V., Burnett J.C. Jr. Specificity of C-type and atrial natriuretic peptides in human blood vessels. Endothelium. 4:1996;23-28.
26. Nazario B., Hu R.M., Pedram A., Prins B., Levin E.R. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest. 95:1995;1151-1157.
27. Fennesy P.A., Campbell J., Campbell G.R. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and the lipoprotein binding to smooth muscle cells in culture. Atherosclerosis. 106:1994;29-41.
28. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.A., Billingham M.E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
29. Osborne J.A., Lento P.H., Siegfried M.R., Stahl G.L., Fusman B., Lefer A.M. Cardiovascular effects of acute hypercholesterolemia in rabbits reversal with lovastatin treatment . J Clin Invest. 83:1989;465-473.
30. Lerman A., Burnett J.C. Jr, Higano S.T., McKinley L.J., Holmes D.R. Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 97:1998;2123-2128.